Shire PLC (SHPG) filed a Form 8K - Changes in Company Executive
Management - with the U.S Securities and Exchange Commission on
November 19, 2014.
As Shire plc ("Shire") previously announced on Form 8-K filed
October 20, 2014, James Bowling will be stepping down as interim
Chief Financial Officer ("CFO") of Shire. On November 19, 2014,
Shire announced that Jeff Poulton (47), Shire's Senior Vice
President and Head of Investor Relations, will succeed Mr. Bowling
as interim CFO with effect from January 1, 2015.
Mr. Poulton joined Shire in 2003 and in addition to his current
role, has served in a number of positions including, in the past
five years, as Senior Vice President and Head of Shire's Rare
Disease Business Unit, Senior Vice President and General Manager
for Americas and Asia Pacific Commercial Operations for Shire's
Human Genetic Therapy Division, and Senior Vice President Finance
for Shire's Human Genetic Therapy Division. Mr. Poulton is expected
to enter into a new employment agreement governing the terms of his
appointment as interim CFO.
Shire has issued the press release attached as Exhibit 99.1
hereto which is incorporated by reference herein.
The full text of this SEC filing can be retrieved at:
http://www.sec.gov/Archives/edgar/data/936402/000095010314008291/dp51347_8k.htm
Any exhibits and associated documents for this SEC filing can be
retrieved at:
http://www.sec.gov/Archives/edgar/data/936402/000095010314008291/0000950103-14-008291-index.htm
Public companies must file a Form 8-K, or current report, with
the SEC generally within four days of any event that could
materially affect a company's financial position or the value of
its shares.
Subscribe to WSJ: http://online.wsj.com?mod=djnwires